Previous 10 | Next 10 |
Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 PR Newswire PALO ALTO, Calif. , June 27, 2022 /PRNewswire/ -- Eiger BioPhar...
AbbVie has used a priority review voucher to expand the indication of Rinvoq (upadacitinib) to include moderately to severely active ulcerative colitis. The approval was noted in a Federal Register posting Thursday. Endpoints News reported that the voucher used was likely one Abbvie (NYS...
Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries PR Newswire - Data presented in oral presentation at ENDO 2022 on Jun...
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compou...
Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 PR Newswire - Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PAL...
Commercial-stage biopharmaceutical company focused on innovative therapies to treat and cure hepatitis delta virus, Eiger BioPharmaceuticals (NASDAQ:EIGR -0.6%) entered into a term loan agreement with an affiliate of Innovatus Capital Partners for up to $75M and a stock purchase agreemen...
Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones PR Newswire Eiger nets approximately $11M ...
Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference PR Newswire PALO ALTO, Calif. , June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the devel...
Eiger BioPharmaceuticals (NASDAQ:EIGR) on Friday said that a European Union drug regulator committee had recommended approval of the company's therapy Zokinvy as the first treatment in the region for premature aging, also known as progeria. EIGR stock +3.5% to $6.78 in premarket tra...
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire If authorized, Zokinvy® (lonafarnib) will be the first and only treatment approved in Europe ...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...